Questionnaire on neuropathic pain: a European neurologist survey

A comparison of the DN4 and LANSS questionnaires in the assessment of neuropathic pain: validity and reliability of the Turkish version of DN4

A screening tool that quickly and correctly differentiates neuropathic pain from non-neuropathic pain is essential. Although there are many screening tools in the assessment of neuropathic pain, many physicians still have the problem of not being able to identify their neuropathic pain patients easily. In this study, we assessed the test-retest reliability, internal consistency, and validity of the Turkish version of DN4 questionnaire. Within the same group of patients, we also compared the DN4 with the LANSS questionnaire. A total of 180 patients (n = 121 with neuropathic pain and n = 59 with non-neuropathic pain characteristics) were enrolled. In our study population, peripheral origin of neuropathic pain, mainly radiculopathies and polyneuropathies, dominated. The reliability and validity of Turkish version of DN4 were found to be high. The sensitivities of the DN4 and the LANSS were 95% and 70.2%, respectively. The specificity of both tests was 96.6%. The strengths and weaknesses of these questionnaires are discussed.

PERSPECTIVE

The Turkish version of DN4 questionnaire is reliable and valid. It is also an easier, quicker, and more sensitive screening tool (1-minute test) compared with the Turkish version of LANSS questionnaire. These features of the DN4 may help clinicians to identify their neuropathic pain patients accurately in daily clinical practice and research studies.

A survey of treatment practices in diabetic peripheral neuropathy

OBJECTIVE

To evaluate provider practices for identification and treatment of painful diabetic peripheral neuropathy (DPN).

METHODS

A questionnaire was distributed to healthcare providers attending educational programs in New England.

RESULTS

The survey was completed by 357 providers. Although generally ineffective in neuropathic pain, non-steroidal anti-inflammatory drugs were prescribed by 31% of providers. Only 57% providers used a quantitative pain scale to evaluate pain. The effectiveness of medications was assessed at least frequently by 70% of providers and at every visit by 22% providers.

CONCLUSION

The results reiterate the need for routinely monitoring patients with painful DPN and using appropriate pain scales.